PLANNING PATIENT ENGAGEMENT Tools for the management of competing interests and conflicts of interest Enhancement of the EUPATI industry guidance Recommendations on the required capabilities for PE PE agreements explained Recommendations on how to find th right match for the right PE activity

<u>suite</u>

PFMD Patient engagement management

TRANSCELERATE Patient protocol engagement toolkit

CTTI Recommendations and tools for effective engagement with patient groups around clinical trials

PCORI Patient engagement rubric

NHC Patient engagement recommendations and tools

NHIR INVOLVE resources

CONDUCTING PATIENT ENGAGEMENT

Code of conduct for all stakeholders
involved in PE activities within medicines
development

Working with Community Advisory
Boards: Guidance and tools for patient
communities and pharmaceutical
companies

PE in Early Dialogues: Tools and resources for HTA bodies

PE resources on finacial compensation:

- NHC Fair Market Value Calculator
- NIHR INVOLVE Cost Calculator
- Guiding principles on reasonable agreements between patient advocates and pharmaceutical companies (chapter on financial compensation)
- EFPIA Code of practice
- ABPI Code of practice

REPORTING AND EVALUATION

PE Monitoring and Evaluation Framework

Guidance for reporting and dissemination of patient engagement activities

For patients

- EUPATI Training portfolio
- <u>EUPATI Toolbox on medicines R&D</u>
- EURORDIS Open Academy
- EPF Capacity-building programme

For all stakeholders

- PFMD PE training
- <u>EUPATI Fundamentals Training for</u> <u>professionals on PE</u>
- <u>International Children's Advisory</u> <u>Network educational materials</u>

PE TRAINING RESOURCES

Fig. 4 Integrated resources, guidance and tools covering PE phases

Public-private consortia	European Patients' Academy (EUPATI)
	Patient-Focused Medicines Development (PFMD)
	National Health Council (NHC)
	Clinical Trials Transformation Initiative
	<u>Faster Cures</u>
Harmonisation bodies	The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
	(ICH)
	Council for International Organizations of Medical Sciences (CIOMS)
Supra-national bodies	World Health Organisation (WHO)
Regulatory science platforms	Heads of Medicines Agencies (HMA) network
	International Coalition of Medicines Regulatory Authorities (ICMRA)
Health Technology Assessment	European network for Health Technology Assessment (EUnetHTA)
and medicines pricing and	Health Technology Assessment international (HTAi)
reimbursement networks	Medicine Evaluation Committee (MEDEV)
Multi-stakeholder networking platforms	Patient Engagement Open Forum (PEOF)
	The European Federation of Pharmaceutical Industries and Associations (EFPIA) Annual Conference
	European Medicines Agency Patients' and Consumers Working Party
	European Federation of Pharmaceutical Industries and Associations (EFPIA) Patient Think Tank
	European Patients Forum (EPF) Congress on Patient Involvement
	European Conference on Rare Diseases (ECRD)
	Health Technology Assessment International (HTAi) Annual Meeting
	Drug Information Association (DIA)
	Biotechnology Innovation Organization
	Partnering for cures (Faster Cures)
	<u>International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Patient Representative</u>
	Roundtable 2
	ISPOR conferences
	PFMD Synapse for patient engagement

Fig. 5 Platforms important for PE sustainability